Position in ANAB
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,957,985
-$815,897 QoQ
Shares Held
43,822
-57.1% QoQ
Ownership
0.151%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#60
of 211 holders
Holding Since
Mar 2023
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names. ANAB ranks #123 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in ANAB
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,957,985 | 43,822 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $3,773,882 | 68,047 | Shares | Other | 2026-05-15 | |
| 2025-09-30 | $1,666,214 | 54,416 | Shares | Other | 2025-11-13 | |
| 2025-03-31 | $1,726,448 | 92,870 | Shares | Other | 2025-05-15 | |
| 2024-09-30 | $300,762 | 8,978 | Shares | Other | 2024-11-14 | |
| 2023-12-31 | $714,506 | 33,357 | Shares | Other | 2024-02-14 | |
| 2023-09-30 | $626,389 | 34,877 | Shares | Other | 2023-11-14 | |
| 2023-06-30 | $270,542 | 13,301 | Shares | Other | 2023-08-14 | |
| 2023-03-31 | $530,879 | 24,397 | Shares | Other | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||